Metabolic syndrome: From global epidemiology to individualized medicine

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 5, 2007, Pages 509-524

  Batsis, J A ^a   Nieto Martinez, R E ^b,c   Lopez Jimenez, F ^a  

^a Mayo Clinic   (United States)

^b UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

^c Metabolism and Nutrition Unit ^*  (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN; EXANETIDE; FENOFIBRATE; GEMFIBROZIL; GLIMEPIRIDE; INCRETIN; METFORMIN; MURAGLITAZAR; PHENTERMINE; PIOGLITAZONE; PRAMLINTIDE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SOYBEAN PROTEIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ORGANIZATION; HEALTH SURVEY; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; STROKE; WAIST CIRCUMFERENCE;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; BIGUANIDES; BODY MASS INDEX; CALORIC RESTRICTION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EUROPE; EXERCISE; FOOD HABITS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LIFE STYLE; MEDITERRANEAN REGION; METABOLIC SYNDROME X; MEXICAN AMERICANS; MEXICO; NUTRITION SURVEYS; OBESITY; PREVALENCE; RISK FACTORS; UNITED STATES; WAIST-HIP RATIO;

EID: 35448950424     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100355     Document Type: Review

References (134)

1. Kylin, E. Studien uber das Hypertonie-Hyperglykamie-Hyperurikamiesyndrom. Zentrabl. finnere. Med. Leipz. 81, 105-127 (1923).
2. Vague, J. Sexual differentiation, a factor affecting the forms of obesity. Presse Med. 30, 339-340 (1947).
3. Albrink, M.J. & Meigs, J.W. The relationship between serum triglycerides and skinfold thickness in obese subjects. Ann. NY Acad. Sci. 131, 673-683 (1965).
4. Avogaro, P., Battaglia, G., Pujatti, G., Chioin, R. & Locatelli, C. On an unusual syndrome of supravalvular aortic stenosis, mental retardation and hypercalcemic facies. Mal. Cardiovasc. 8, 631-647 (1967).
5. Reaven, G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
6. Alberti, K.G. & Zimmet, P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539-553 (1998).
7. Alberti, K.G., Zimmet, P. & Shaw, J. The metabolic syndrome - a new worldwide definition. Lancet 366, 1059-1062 (2005).
8. Balkau, B. & Charles, M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med. 16, 442-443 (1999).
9. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
10. Grundy, S.M. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752 (2005).
11. Einhorn, D. et al. American college of endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237-252 (2003).
12. Genuth, S. et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26, 3160-3167 (2003).
13. Gami, A.S. et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and metaanalysis of longitudinal studies. J. Am. Coll. Cardiol. 49, 403-414 (2007).
14. Florez, H. et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res. Clin. Pract. 69, 63-77 (2005).
15. Barbosa, P.J., Lessa, I., de Almeida Filho, N., Magalhaes, L.B. & Araujo, J. Criteria for central obesity in a Brazilian population: impact on metabolic syndrome. Arq. Bras. Cardiol. 87, 407-414 (2006).
16. de Oliveira, E.P., de Souza, M.L. & de Lima, M.D. Prevalence of metabolic syndrome in a semi-arid rural area in Bahia. Arq. Bras. Endocrinol. Metabol. 50, 456-465 (2006).
17. Ramirez-Vargas, E., Arnaud-Vinas, M.D. & Delisle, H. Prevalence of the metabolic syndrome and associated lifestyles in adult males from Oaxaca, Mexico. Salud Publica Mex. 49, 94-102 (2007).
18. Chedraui, P. et al. Quality of life among postmenopausal Ecuadorian women participating in a metabolic syndrome screening program. Maturitas 56, 45-53 (2007).
19. Royer, M. et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric 10, 164-170 (2007).
20. Araneta, M.R., Wingard, D.L. & Barrett-Connor, E. Type 2 diabetes and metabolic syndrome in Filipina-American women: a high-risk nonobese population. Diabetes Care 25, 494-499 (2002).
21. Flegal, K.M., Carroll, M.D., Kuczmarski, R.J. & Johnson, C.L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int. J. Obes. Relat. Metab. Disord. 22, 39-47 (1998).
22. Ogden, C.L. et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295, 1549-1555 (2006).
23. Ford, E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 28, 2745-2749 (2005).
24. Ford, E.S., Giles, W.H. & Dietz, W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359 (2002).
25. Park, Y.W. et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch. Intern. Med. 163, 427-436 (2003).
26. de Ferranti, S.D. et al. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 110, 2494-2497 (2004).
27. Cook, S., Weitzman, M., Auinger, P., Nguyen, M. & Dietz, W.H. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch. Pediatr. Adolesc. Med. 157, 821-827 (2003).
28. Cameron, A.J., Shaw, J.E. & Zimmet, P.Z. The metabolic syndrome: prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 33, 351-375; table of contents (2004).
29. Laaksonen, D.E. et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 156, 1070-1077 (2002).
30. Balkau, B. et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 28, 364-376 (2002).
31. Gupta, A. et al. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res. Clin. Pract. 61, 69-76 (2003).
32. Deepa, R., Shanthirani, C.S., Premalatha, G., Sastry, N.G. & Mohan, V. Prevalence of insulin resistance syndrome in a selected south Indian population - the Chennai urban population study-7 [CUPS-7]. Indian J. Med. Res. 115, 118-127 (2002).
33. Ramachandran, A., Snehalatha, C., Satyavani, K., Sivasankari, S. & Vijay, V. Metabolic syndrome in urban Asian Indian adults - a population study using modified ATP III criteria. Diabetes Res. Clin. Pract. 60, 199-204 (2003).
34. Azizi, F., Salehi, P., Etemadi, A. & Zahedi-Asl, S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res. Clin. Pract. 61, 29-37 (2003).
35. Centers for Disease Control. The National Health and Nutrition Examination Surveys 〈http://www.cdc.gov/nchs/nhanes.htm〉. Accessed 10 July 2007.
36. Onat, A. et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 165, 285-292 (2002).
37. Villareal, D.T. et al. Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. Am. J. Clin. Nutr. 84, 1317-1323 (2006).
38. Florez, H. et al. Metabolic syndrome Increases diabetes risk in IGT subjects: effects across diabetes prevention program interventions. Abstract 1299-P. American Diabetes Association 67th Scientific Session (Chicago, IL, 2007); Diabetes 56(6): Supplement June 2007.
39. Galassi, A., Reynolds, K. & He, J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med. 119, 812-819 (2006).
40. Malik, S. et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110, 1245-1250 (2004).
41. Isomaa, B. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689 (2001).
42. Tong, W. et al. Age, gender and metabolic syndrome-related coronary heart disease in US adults. Int. J. Cardiol. 104, 288-291 (2005).
43. McNeill, A.M. et al. Metabolic syndrome and cardiovascular disease in older people: The Cardiovascular Health Study. J. Am. Geriatr. Soc. 54, 1317-1324 (2006).
44. McNeill, A.M. et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28, 385-390 (2005).
45. Hunt, K.J., Resendez, R.G., Williams, K., Haffner, S.M. & Stern, M.P. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110, 1251-1257 (2004).
46. Sattar, N. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108, 414-419 (2003).
47. Lorenzo, C., Williams, K., Gonzalez-Villalpando, C. & Haffner, S.M. The prevalence of the metabolic syndrome did not increase in Mexico City between 1990-1992 and 1997-1999 despite more central obesity. Diabetes Care 28, 2480-2485 (2005).
48. Wannamethee, S.G., Shaper, A.G., Lennon, L. & Morris, R.W. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch. Intern. Med. 165, 2644-2650 (2005).
49. Wilson, P.W., D'Agostino, R.B., Parise, H., Sullivan, L. & Meigs, J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112, 3066-3072 (2005).
50. Tong, P.C. et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 30, 1206-1211 (2007).
51. Carle, F. et al. Diabetes incidence in 0- to 14-year age-group in Italy: a 10-year prospective study. Diabetes Care 27, 2790-2796 (2004).
52. Bruno, G. et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27, 2689-2694 (2004).
53. Cerutti, F. et al. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study. Diabetes Care 27, 1294-1298 (2004).
54. Yano, Y. et al. Tumor necrosis factor-alpha is associated with increased protein C activation in nonobese type 2 diabetic patients. Diabetes Care 27, 844-845 (2004).
55. Kahn, R., Buse, J., Ferrannini, E. & Stern, M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28, 2289-2304 (2005).
56. Grundy, S.M., Pasternak, R., Greenland, P., Smith, S. Jr. & Fuster, V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100, 1481-1492 (1999).
57. Assmann, G. et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am. J. Cardiol. 99, 541-548 (2007).
58. Athyros, V.G. et al. Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J. Cardiol. 46, 380-386 (2005).
59. Guerrero-Romero, F. & Rodriguez-Moran, M. Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions. Diabetes Care 28, 2588-2589 (2005).
60. Adams, R.J. et al. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care 28, 2777-2779 (2005).
61. Pauker, S.G. & Kassirer, J.P. The threshold approach to clinical decision making. N. Engl. J. Med. 302, 1109-1117 (1980).
62. Chobanian, A.V. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
63. Stamler, J., Vaccaro, O., Neaton, J.D. & Wentworth, D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434-444 (1993).
64. Rowland, M.L. Self-reported weight and height. Am. J. Clin. Nutr. 52, 1125-1133 (1990).
65. Wilson, P.W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998).
66. Stevens, R.J., Kothari, V., Adler, A.I. & Stratton, I.M. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin. Sci. (Lond) 101, 671-679 (2001).
67. McLaughlin, T. et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. 139, 802-809 (2003).
68. Ferrannini, E. & Balkau, B. Insulin: in search of a syndrome. Diabet. Med. 19, 724-729 (2002).
69. Reaven, G.M. The metabolic syndrome: requiescat in pace. Clin. Chem. 51, 931-938 (2005).
70. Fonseca, V.A. The metabolic syndrome, hyperlipidemia, and insulin resistance. Clin. Cornerstone 7, 61-72 (2005).
71. D'Agostino, R.B. Sr., Grundy, S., Sullivan, L.M. & Wilson, P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286, 180-187 (2001).
72. Eckel, R.H., Kahn, R., Robertson, R.M. & Rizza, R.A. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 113, 2943-2946 (2006).
73. Wannamethee, S.G. & Shaper, A.G. Physical activity in the prevention of cardiovascular disease: an epidemiological perspective. Sports Med. 31, 101-114 (2001).
74. Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001).
75. Ekelund, U. et al. Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians: the Medical Research Council Ely Study. Diabetes Care 28, 1195-1200 (2005).
76. Frank, L.L. et al. Effects of exercise on metabolic risk variables in overweight postmenopausal women: a randomized clinical trial. Obes. Res. 13, 615-625 (2005).
77. Cox, K.L., Burke, V., Morton, A.R., Beilin, L.J. & Puddey, I.B. Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men. Am. J. Clin. Nutr. 80, 308-316 (2004).
78. Rice, B., Janssen, I., Hudson, R. & Ross, R. Effects of aerobic or resistance exercise and/or diet on glucose tolerance and plasma insulin levels in obese men. Diabetes Care 22, 684-691 (1999).
79. Torjesen, P.A. et al. Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. Diabetes Care 20, 26-31 (1997).
80. Katzmarzyk, P.T., Church, T.S. & Blair, S.N. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch. Intern. Med. 164, 1092-1097 (2004).
81. Katzmarzyk, P.T., Church, T.S., Janssen, I., Ross, R. & Blair, S.N. Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Diabetes Care 28, 391-397 (2005).
82. Dansinger, M.L., Gleason, J.A., Griffith, J.L., Selker, H.P. & Schaefer, E.J. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293, 43-53 (2005).
83. Lichtenstein, A.H. et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 114, 82-96 (2006).
84. Kris-Etherton, P., Eckel, R.H., Howard, B.V., St Jeor, S. & Bazzarre, T.L. AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. Circulation 103, 1823-1825 (2001).
85. Esposito, K. et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292, 1440-1446 (2004).
86. Estruch, R. et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann. Intern. Med. 145, 1-11 (2006).
87. Stern, L. et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann. Intern. Med. 140, 778-785 (2004).
88. Azadbakht, L. et al. Soy inclusion in the diet improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women. Am. J. Clin. Nutr. 85, 735-741 (2007).
89. Orchard, T.J. et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142, 611-619 (2005).
90. Knowler, W.C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
91. Derosa, G. et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern. Med. J. 37, 79-86 (2007).
92. Derosa, G. et al. Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. J. Int. Med. Res. 33, 284-294 (2005).
93. Nissen, S.E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
94. American Diabetes Association: Complications of Diabetes in the United States 〈http://www.diabetes.org/diabetes-statistics/complications. jsp〉. Accessed 12 July 2007.
95. Home, P.D. et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N. Engl. J. Med. 357, 28-38 (2007).
96. Davidson, M.H. et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281, 235-242 (1999).
97. Sjostrom, L. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352, 167-172 (1998).
98. Tzotzas, T., Samara, M., Constantinidis, T., Tziomalos, K. & Krassas, G. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome. Angiology 58, 26-33 (2007).
99. Didangelos, T.P. et al. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr. Med. Res. Opin. 20, 1393-1401 (2004).
100. Zanella, M.T. et al. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study. Arq. Bras. Endocrinol. Metabol. 50, 368-376 (2006).
101. Torgerson, J., Hauptman, J. & Boldrin, M. Efficacy of orlistat plus lifestyle changes in risk reduction of type 2 diabetes in obese patients with metabolic syndrome: a comparative analysis using National cholesterol Education Program Adult Treatment Panel III vs European Group for the Study of Insulin Resistance criteria. Diabetologia 47, A249 (2004).
102. Filippatos, T.D. et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr. Med. Res. Opin. 21, 1997-2006 (2005).
103. James, W.P. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356, 2119-2125 (2000).
104. Wadden, T.A. et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med. 353, 2111-2120 (2005).
105. Haddock, C.K., Poston, W.S., Dill, P.L., Foreyt, J.P. & Ericsson, M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord. 26, 262-273 (2002).
106. Pagotto, U. & Pasquali, R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 365, 1363-1364 (2005).
107. Cota, D. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423-431 (2003).
108. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J. & Rosenstock, J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIONorth America: a randomized controlled trial. JAMA 295, 761-775 (2006).
109. Hollander, P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am. J. Med. 120, S18-S28; discussion S29-S32 (2007).
110. Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D. & Van Gaal, L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368, 1660-1672 (2006).
111. Despres, J.P., Golay, A. & Sjostrom, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121-2134 (2005).
112. Pope, G.D., Birkmeyer, J.D. & Finlayson, S.R. National trends in utilization and in-hospital outcomes of bariatric surgery. J. Gastrointest. Surg. 6, 855-860; discussion 861 (2002).
113. Sjostrom, L. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004).
114. Lopez-Jimenez, F., Bhatia, S., Collazo-Clavell, M.L., Sarr, M.G. & Somers, V.K. Safety and efficacy of bariatric surgery in patients with coronary artery disease. Mayo Clin. Proc. 80, 1157-1162 (2005).
115. Buchwald, H. et al. Bariatric surgery: a systematic review and metaanalysis. JAMA 292, 1724-1737 (2004).
116. Batsis, J.A. et al. Effect of weight loss on predicted cardiovascular risk: change in cardiac risk after bariatric surgery. Obesity (Silver Spring) 15, 772-784 (2007).
117. Torquati, A., Wright, K., Melvin, W. & Richards, W. Effect of gastric bypass operation on Framingham and actual risk of cardiovascular events in class II-III obesity. J. Am. Coll. Surg. 204, 776-782 (2007).
118. Vogel, J.A. et al. Reduction in predicted coronary heart disease risk after substantial weight reduction after bariatric surgery. Am. J. Cardiol. 99, 222-226 (2007).
119. MacDonald, K.G. Jr. et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J. Gastrointest. Surg. 1, 213-220; discussion 220 (1997).
120. Sampalis, J.S., Sampalis, F. & Christou, N. Impact of bariatric surgery on cardiovascular and musculoskeletal morbidity. Surg. Obes. Relat. Dis. 2, 587-591 (2006).
121. Gazzaruso, C. et al. Weight loss after Swedish adjustable gastric banding: relationships to insulin resistance and metabolic syndrome. Obes. Surg. 12, 841-845 (2002).
122. Mattar, S.G. et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann. Surg. 242, 610-617; discussion 618-620 (2005).
123. Coppini, L.Z., Bertevello, P.L., Gama-Rodrigues, J. & Waitzberg, D.L. Changes in insulin sensitivity in morbidly obese patients with or without metabolic syndrome after gastric bypass. Obes. Surg. 16, 1520-1525 (2006).
124. Madan, A.K., Orth, W., Ternovits, C.A. & Tichansky, D.S. Metabolic syndrome: yet another co-morbidity gastric bypass helps cure. Surg. Obes. Relat. Dis. 2, 48-51; discussion 51 (2006).
125. Giusti, V., Suter, M., Heraief, E., Gaillard, R.C. & Burckhardt, P. Effects of laparoscopic gastric banding on body composition, metabolic profile and nutritional status of obese women: 12-months follow-up. Obes. Surg. 14, 239-245 (2004).
126. Larrad Jimenez, A. et al. Course of metabolic syndrome following the biliopancreatic diversion of Larrad. Obes. Surg. 14, 1176-1181 (2004).
127. Lee, W.J. et al. Effects of obesity surgery on the metabolic syndrome. Arch. Surg. 139, 1088-1092 (2004).
128. Blonde, L. et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. 8, 436-447 (2006).
129. Zinman, B. et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 146, 477-485 (2007).
130. Thompson, R.G., Pearson, L., Schoenfeld, S.L. & Kolterman, O.G. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care 21, 987-993 (1998).
131. Hollander, P.A. et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26, 784-790 (2003).
132. Buse, J.B. et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin. Ther. 27, 1181-1195 (2005).
133. Nissen, S.E., Wolski, K. & Topol, E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294, 2581-2586 (2005).
134. Gentles, D. et al. Metabolic syndrome prevalence in a multicultural population in Auckland, New Zealand. N. Z. Med. J. 120, U2399 (2007).